Is This The Future Of Late-Stage Drug Development?

On Friday, Novartis announced that its anti-IL17A antibody secukinumab (Cosentyx™) demonstrated clear superiority over its rival, Stelara™ ustekinumab from Johnson & Johnson, an antibody against IL-12 and IL-23, in the treatment of psoriasis.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news